Literature DB >> 27698845

Multidisciplinary collaboration in gallbladder carcinoma treatment: A case report and literature review.

Zheng-Yun Zou1, Jing Yan1, Yu-Zheng Zhuge2, Jun Chen3, Xiao-Ping Qian1, Bao-Rui Liu1.   

Abstract

Gallbladder carcinoma (GBC) is a rare and highly aggressive disease. The diagnosis of this cancer is difficult due to its occult onset. Hence, GBC is often detected late and at an advanced stage. Although physicians and researchers are continually working to improve the treatment for advanced-stage disease, GBC is usually associated with short survival times. The present study describes a case of GBC that was first diagnosed with accompanying cholecystolithiasis at the time of cholecystectomy. Cancer relapse occurred 1.5 years after the cholecystectomy. Multidisciplinary collaboration was involved in the decision-making process for the treatment of this aggressive recurrence, and the survival time was successfully extended to 26 months. Importantly, high-grade intraepithelial neoplasia and positive margins had previously been detected post-cholecystectomy at a different institution, but were ignored. Relapse may have been preventable had the cancer been diagnosed when it was initially observed. Taken together, these findings suggest that multidisciplinary collaboration should be considered for the management of advanced GBC, whereby patients will benefit from improved survival times. Furthermore, it is recommended that samples obtained from patients undergoing cholecystectomy should more carefully analyzed for evidence of cancerous or precancerous tissues.

Entities:  

Keywords:  cancerous or precancerous tissue; cholecystectomy; gallbladder carcinoma; multidisciplinary collaboration; survival times

Year:  2016        PMID: 27698845      PMCID: PMC5038553          DOI: 10.3892/ol.2016.5020

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  21 in total

1.  Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.

Authors:  Hitoshi Kuriyama; Kenichi Kawana; Reo Taniguchi; Fumitake Jono; Eiji Sakai; Hidenori Okubo; Hirobumi Suzuki; Satoshi Kobayashi; Yoriko Murata; Masahiko Inamori; Yasuo Hata; Atsushi Nakajima
Journal:  Hepatogastroenterology       Date:  2011 Jan-Feb

2.  Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

Authors:  Birgit Gruenberger; Johannes Schueller; Ute Heubrandtner; Fritz Wrba; Dietmar Tamandl; Klaus Kaczirek; Rudolf Roka; Sandra Freimann-Pircher; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2010-11-09       Impact factor: 41.316

3.  Intensity-modulated radiotherapy in the treatment of subhepatic carcinomas.

Authors:  Jirí Petera; Linda Kasaová; Petr Paluska; Igor Sirák; Jan Jansa; Zuzana Macingová; Josef Dvorák; Renata Soumarova
Journal:  Hepatogastroenterology       Date:  2011 Mar-Apr

Review 4.  Epidemiology and molecular pathology of gallbladder cancer.

Authors:  E C Lazcano-Ponce; J F Miquel; N Muñoz; R Herrero; C Ferrecio; I I Wistuba; P Alonso de Ruiz; G Aristi Urista; F Nervi
Journal:  CA Cancer J Clin       Date:  2001 Nov-Dec       Impact factor: 508.702

5.  Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.

Authors:  Ping-Ying Chang; Ming-Fang Cheng; Herng-Sheng Lee; Chung-Bao Hsieh; Nai-Shun Yao
Journal:  Onkologie       Date:  2010-01-22

6.  Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.

Authors:  Kerry J Williams; Joel Picus; Kim Trinkhaus; Chloe C Fournier; Rama Suresh; Joan S James; Benjamin R Tan
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

7.  Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.

Authors:  Pierpaolo Correale; Maria Grazia Cusi; Kwong Yok Tsang; Maria Teresa Del Vecchio; Stefania Marsili; Marco La Placa; Chiara Intrivici; Angelo Aquino; Lucia Micheli; Cristina Nencini; Francesco Ferrari; Giorgio Giorgi; Enzo Bonmassar; Guido Francini
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

Review 8.  The anticancer immune response: indispensable for therapeutic success?

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

9.  Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer.

Authors:  J Harder; B Riecken; O Kummer; C Lohrmann; F Otto; H Usadel; M Geissler; O Opitz; H Henss
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

10.  Phase II study of S-1 in patients with advanced biliary tract cancer.

Authors:  H Ueno; T Okusaka; M Ikeda; Y Takezako; C Morizane
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

View more
  1 in total

1.  Effects of multidisciplinary model of damage control on acute cervical spinal cord injury in winter Olympic sports.

Authors:  Peinan Zhang; Xinming Yang; Yanlin Yin; Zhenliang Zhang; Yao Yao
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.